ストックスクリーナーアプリを入手
60.77
8.00%
4.50
アフターアワーズ：
60.61
-0.16
-0.26%
Arrowhead Pharmaceuticals Inc (ARWR) 最新ニュース
Leerink reiterates Arrowhead Pharma stock rating on partner data By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals Surges as Clinical Trial Doses First Patients - StocksToTrade
Arrowhead Pharma (ARWR) Rating Reiterated as 'Buy' by HC Wainwri - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from HC Wainwright - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 8.6%Here's What Happened - MarketBeat
Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets - Barron's
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Nordea Investment Management AB - MarketBeat
Assenagon Asset Management S.A. Purchases 304,264 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
JPMorgan Chase & Co. Grows Stake in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Exit Recap: Whats the beta of Arrowhead Pharmaceuticals Inc stockWeekly Gains Summary & High Yield Equity Trading Tips - baoquankhu1.vn
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Hudson Bay Capital Management LP - MarketBeat
Arrowhead (ARWR) FQ1 2026 revenue hits $264M as REDEMPLO approval marks commercial shift - MSN
Arrowhead Shareholders Reject Say-on-Pay at 2026 Meeting - The Globe and Mail
B of A Securities Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation - MSN
Arrowhead Pharmaceuticals (NASDAQ: ARWR) holders back board but reject Say-on-Pay - Stock Titan
Arrowhead Advances Zodasiran Into Phase 3 HoFH Study, Signaling Long-Term Growth Potential - TipRanks
A Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Recent Momentum Cools After A Strong Run - Yahoo Finance
Arrowhead’s bid to become a large-cap biotech - BioCentury
Arrowhead Pharmaceuticals (ARWR) price target increased by 17.24% to 59.24 - MSN
A Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Fisher Builds Stake And SHASTA Readouts Approach - Sahm
Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma - Insider Monkey
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
Arrowhead Pharmaceuticals (ARWR) Is Down 5.4%What's Changed - simplywall.st
Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics - MSN
How Arrowhead Pharmaceuticals Inc. (ARWR) Affects Rotational Strategy Timing - Stock Traders Daily
Fred Alger Management LLC Acquires New Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Bought by Boothbay Fund Management LLC - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Is Down 5.4% After First Drug REDEMPLO Wins FDA ApprovalWhat's Changed - Sahm
Baker BROS. Advisors LP Purchases 731,588 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift - Insider Monkey
Analyst Upgrade: Can Arrowhead Pharmaceuticals Inc scale operations efficiently2026 Technical Overview & Precise Swing Trade Alerts - baoquankhu1.vn
225,000 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Bought by Integral Health Asset Management LLC - MarketBeat
Avoro Capital Advisors LLC Has $375.94 Million Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
siRNA Therapeutics Market Poised for Rapid Growth to US$ 12.38 - openPR.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Arrowhead Pharmaceuticals Teases Q3 Data Wave: SHASTA-3/4, RNAi Dimer and ARO-MAPT Readouts Ahead - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider James Hamilton Sells 10,000 Shares - MarketBeat
Hamilton James, Arrowhead Pharmaceuticals CMO, sells $641,900 in stock By Investing.com - Investing.com UK
Hamilton James, Arrowhead Pharmaceuticals CMO, sells $641,900 in stock - Investing.com
Arrowhead Pharmaceuticals CMO Sells 10,000 Shares - TradingView
Arrowhead (NASDAQ: ARWR) CMO sells 10,000 shares in planned Form 4 trade - Stock Titan
Arrowhead Pharmaceuticals at Leerink Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Citigroup Inc. - MarketBeat
Arrowhead Pharmaceuticals Q1 2026 earnings preview - MSN
ARWR SEC FilingsArrowhead Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Intech Investment Management LLC - MarketBeat
Piper Sandler maintains an overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR) - MSN
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 8%What's Next? - MarketBeat
Proposed 10,000-share sale via Merrill Lynch by ARWR (NASDAQ: ARWR) - Stock Titan
Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference - MarketBeat
Rafferty Asset Management LLC Sells 27,546 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Fisher Asset Management LLC Acquires 602,139 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
1.82%
大文字化:
|
ボリューム (24 時間):